Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PROMETHAZINE HYDROCHLORIDE vs PHENERGAN VC
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Promethazine is a phenothiazine derivative that acts as a histamine H1 receptor antagonist, blocking the effects of histamine at H1 receptors. It also has anticholinergic, antiemetic, sedative, and antidopaminergic properties.
Phenergan VC is a combination of promethazine (a phenothiazine derivative with antihistaminic, sedative, antiemetic, and anticholinergic effects) and phenylephrine (a sympathomimetic amine that acts as a decongestant via alpha-1 adrenergic receptor agonism). Promethazine antagonizes H1 receptors, thereby suppressing allergic reactions and motion sickness. Phenylephrine causes vasoconstriction in the nasal mucosa, reducing congestion.
Allergic conditions (e.g., rhinitis, urticaria),Nausea and vomiting,Motion sickness,Sedation (preoperative, postoperative, or obstetrical),Off-label: Anxiety, insomnia
Symptomatic relief of upper respiratory symptoms associated with allergic rhinitis or the common cold,Nasal congestion,Sneezing,Rhinorrhea,Off-label: sedation, nausea/vomiting (promethazine component)
25-50 mg intramuscular or intravenous injection every 4-6 hours as needed; also 12.5-25 mg orally every 4-6 hours.
10-20 m L orally every 4-6 hours as needed; each 5 m L contains 6.25 mg promethazine HCl and 5 mg phenylephrine HCl.
Terminal elimination half-life is 10-19 hours in adults; prolonged in hepatic impairment (up to 30+ hours) and in elderly.
9-16 hours; prolonged in hepatic impairment.
Primarily hepatic metabolism via CYP2D6 to promethazine sulfoxide and other metabolites; also undergoes S-oxidation and N-demethylation.
No specific dose adjustment recommended; use with caution in severe renal impairment (Cr Cl <10 m L/min) due to risk of accumulation.
GFR 30-60 m L/min: administer with caution; GFR <30 m L/min: avoid use due to risk of accumulation of promethazine metabolites.
Promethazine is contraindicated in children less than 2 years of age due to risk of fatal respiratory depression. Use in children 2 years and older should be avoided with other respiratory depressants.
First trimester: Limited human data, no increased risk of major malformations from population-based studies. Second and third trimesters: Use associated with transient neonatal extrapyramidal signs, sedation, withdrawal symptoms if used near term. May inhibit neonatal platelet aggregation.
First trimester: Limited human data; animal studies show no consistent malformations. Second/third trimester: Risk of neonatal respiratory depression, hypotonia, and withdrawal if used near term. Avoid in late pregnancy due to risk of Kernicterus in jaundiced neonates (sulfite component).
Promethazine hydrochloride is a phenothiazine derivative with strong antihistaminic, antiemetic, sedative, and anticholinergic properties. It is contraindicated in children under 2 years due to risk of fatal respiratory depression. Avoid intra-arterial or subcutaneous administration due to risk of tissue necrosis. Use with caution in patients with asthma, COPD, sleep apnea, myasthenia gravis, and prostate hypertrophy. May cause QT prolongation; monitor ECG in at-risk patients. For severe extravasation, treat with phentolamine. Can interfere with urine glucose tests and pregnancy tests.
PHENERGAN VC combines promethazine (an antihistamine/antiemetic) and phenylephrine (a decongestant). Avoid use in children <2 years due to risk of fatal respiratory depression. Monitor for CNS depression, especially with concurrent CNS depressants. Contraindicated in patients with severe hypertension or coronary artery disease due to phenylephrine component.
No interactions on record
No interactions on record
PROMETHAZINE HYDROCHLORIDE and PHENERGAN VC are distinct pharmacological agents. PROMETHAZINE HYDROCHLORIDE belongs to the Antihistamine / Antiemetic class and is primarily used for Allergic conditions (e.g., rhinitis, urticaria)Nausea and vomitingMotion sicknessSedation (preoperative, postoperative, or obstetrical)Off-label: Anxiety, insomnia. PHENERGAN VC belongs to the Antihistamine/Decongestant Combination class and is primarily used for Symptomatic relief of upper respiratory symptoms associated with allergic rhinitis or the common coldNasal congestionSneezingRhinorrheaOff-label: sedation, nausea/vomiting (promethazine component). Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. PROMETHAZINE HYDROCHLORIDE carries a safety status of Category A/B, whereas PHENERGAN VC safety is classified as Category C. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Promethazine undergoes hepatic metabolism primarily via CYP2D6 and to a lesser extent by other CYP enzymes. Phenylephrine is metabolized in the liver by monoamine oxidase (MAO) and sulfotransferase.
Primarily hepatic metabolism; renal excretion of metabolites accounts for <1% of unchanged drug; biliary/fecal excretion of metabolites ~70-80%.
Renal: 70-80% as metabolites; biliary/fecal: 20-30%.
93% bound primarily to albumin.
76-90% bound to albumin.
9-16 L/kg; indicates extensive tissue distribution and accumulation in tissues.
13-18 L/kg; extensive tissue distribution.
Oral: ~25% due to first-pass metabolism; IM: ~70-80%; IV: 100%; rectal: ~25-30%.
Oral: 25-70% due to first-pass effect; IM: 85-95%.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50%; Class C: avoid use or reduce dose by 75%.
Child-Pugh Class A: no adjustment needed; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: contraindicated.
2-6 years: 5-6.25 mg orally every 4-6 hours; 6-12 years: 6.25-12.5 mg orally every 4-6 hours; >12 years: as adult; intramuscular: 0.25-0.5 mg/kg every 4-6 hours.
Children 2-5 years: 5-10 m L orally every 4-6 hours; 6-12 years: 10-15 m L orally every 4-6 hours; not recommended for children under 2 years due to risk of respiratory depression.
Start at lowest effective dose (e.g., 12.5 mg orally or 12.5-25 mg IM/IV); increase cautiously due to increased risk of sedation, confusion, and anticholinergic effects.
Initiate at the lower end of the dosing range (e.g., 10 m L orally every 6 hours) due to increased sensitivity to anticholinergic effects and risk of sedation, confusion, and hypotension; avoid prolonged use.
WARNING: RESPIRATORY DEPRESSION IN CHILDREN. Promethazine is contraindicated in children younger than 2 years due to the risk of fatal respiratory depression. Use in children aged 2 years and older with caution and at lowest effective dose.
Avoid alcohol and CNS depressants. No significant food interactions; may be taken with food if gastric upset occurs. Grapefruit juice may increase systemic exposure? (Not well established; consider monitoring for increased sedation).
Avoid alcohol and grapefruit juice. Alcohol increases CNS depression; grapefruit juice may enhance phenylephrine effects. No significant food restrictions otherwise.
Promethazine is excreted in breast milk in low concentrations; M/P ratio not established. Due to risk of drowsiness and irritability in nursing infants avoid use, especially in neonates or preterm infants. AAP classifies as compatible but caution advised.
Excreted in breast milk in low amounts (M/P ratio unknown for promethazine; phenylephrine M/P ratio ~0.3). Potential for infant sedation, irritability, and decreased milk supply (phenylephrine). Use only if benefit outweighs risk.
No pharmacokinetic data necessitating dose adjustment; however, use lowest effective dose due to potential fetal risks.
No specific dose adjustment recommended; use lowest effective dose for shortest duration. Avoid in preeclampsia/hypertension due to phenylephrine. Pharmacokinetic changes in pregnancy (increased volume of distribution, enhanced clearance) may require higher doses but not systematically studied.
Do not use in children under 2 years old; use with caution in children over 2.,May cause severe drowsiness; do not drive or operate heavy machinery.,Avoid alcohol and other CNS depressants.,Report any muscle stiffness, tremor, or involuntary movements.,If using for motion sickness, take at least 30 minutes before travel.,Do not take with other antihistamines or cold medications.,May cause dry mouth; use sugar-free candy or ice chips.,If you have a history of seizures, asthma, or glaucoma, discuss with your doctor.
Do not use in children under 2 years old due to risk of serious breathing problems.,May cause drowsiness; avoid driving or operating heavy machinery until you know how this medication affects you.,Avoid alcohol and other sedatives while taking this medication.,Phenylephrine can raise blood pressure; monitor if you have high blood pressure or heart problems.,Take folic acid as directed to prevent neural tube defects.,Do not exceed recommended dose; consult your doctor if symptoms persist.